Common Side Effects of Opdivo
Opdivo (nivolumab), a PD-1 inhibitor used for cancers like melanoma and lung cancer, causes side effects by boosting the immune system, which can attack healthy tissues. The most frequent ones, affecting over 10% of patients in clinical trials, include fatigue (up to 59%), musculoskeletal pain (up to 32%), rash (up to 28%), pruritus (itching, up to 25%), diarrhea (up to 21%), nausea (up to 20%), and decreased appetite (up to 18%).[1][2]
Patients often report these as mild to moderate but persistent, sometimes requiring dose adjustments or breaks.
Serious Immune-Related Side Effects
Opdivo triggers immune-related adverse events (irAEs) in 20-40% of cases, which can be severe or fatal if untreated. Key risks:
- Pneumonitis (lung inflammation): 3-5% incidence, with shortness of breath and cough; grade 3-4 in 1-2%.[1]
- Colitis (colon inflammation): Up to 10%, causing severe diarrhea or bleeding; may need steroids or hospitalization.[2]
- Hepatitis (liver damage): Elevated enzymes in 10-15%, with jaundice in severe cases.[1]
- Endocrinopathies: Thyroid issues (hypo/hyperthyroidism, 15-20%), adrenal insufficiency, or type 1 diabetes (rare but permanent).[2]
- Skin reactions: Severe rash or Stevens-Johnson syndrome (less than 1%, but life-threatening).[1]
These often appear within 3-12 weeks of starting but can occur anytime. Early steroids or immunosuppressants manage most, but 1-2% of patients discontinue therapy.[2]
Side Effects by Combination Therapy
Opdivo is often paired with Yervoy (ipilimumab), increasing toxicity:
- Any-grade adverse events: 96% vs. 82% with Opdivo alone.
- Severe (grade 3-4): 59% vs. 21% monotherapy, mainly diarrhea (16%), fatigue (7%), and colitis (10%).[1][3]
- Liver toxicity jumps to 20-25% in combos.[2]
What Happens If Side Effects Are Ignored?
Untreated irAEs can lead to organ failure, with pneumonitis mortality at 1-2% and colitis requiring colectomy in rare cases. Monitoring with regular bloodwork, imaging, and symptom checks is standard; report fever, persistent cough, or bloody stools immediately.[1]
Differences from Other Immunotherapies
Compared to Keytruda (pembrolizumab), Opdivo has similar irAE profiles but slightly higher skin and GI issues in head-to-head trials. Chemo combos add nausea and hair loss not seen with Opdivo alone.[3]
Patient Management and When to Seek Help
Most side effects resolve with treatment interruption and corticosteroids. Long-term risks include chronic hypothyroidism (10%) or neuropathy. Pregnant patients face fetal harm risks—use contraception.[1][2]
Sources
[1]: Opdivo Prescribing Information (BMS)
[2]: [FDA Label for Nivolumab](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.pdf)
[3]: CheckMate Trials Summary (NEJM)